Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.40 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.35 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | NQO1 | P15559 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14267140 | 0.77 | KEAP1 (0.35) | NOS1KEAP1PSMB8NOS3NOS2 | |
| SCHEMBL12617380 | 0.76 | NPC1 (0.33) | NOS1KEAP1PSMB8NOS3NOS2 | |
| SCHEMBL31373781 | 0.74 | CYP2A6 (0.41) | NOS1KEAP1PSMB8NOS3NOS2 | |
| SCHEMBL12965983 | 0.73 | KEAP1 (0.40) | SMYD3KEAP1PSMB8CYP2A6ALDH1A1 | |
| SCHEMBL4419450 | 0.73 | KEAP1 (0.40) | SMYD3KEAP1PSMB8CYP2A6ALDH1A1 | |
| SCHEMBL3360077 | 0.71 | DAO (0.46) | SMYD3GAACYP1A2KDM4EMAPT | |
| SCHEMBL4430660 | 0.71 | NQO2 (0.42) | NOS1KEAP1CYP2A6GAARXFP1 | |
| SCHEMBL2406831 | 0.70 | SMYD3 (0.53) | SMYD3NOS1NOS3NOS2ALDH1A1 | |
| SCHEMBL1673129 | 0.67 | NOS1 (0.37) | SMYD3NOS1NOS3NOS2CA1 | |
| SCHEMBL13671555 | 0.67 | KDM4E (0.35) | NOS1KEAP1PSMB8NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1715840-B1 | KERATIN DYEING COMPOSITIONS CONTAINING BICYCLIC FUSED 5-5 HETEROAROMATIC DYES | PROCTER & GAMBLE (US) | 2008-12-03 | — | — | EP | claimed |
| US-7303590-B2 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-04 | — | — | US | claimed |
| US-20050193502-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | PROCTER, GAMBLE COMPANY, THE | 2005-09-08 | — | — | US | claimed |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-05 | — | — | US | disclosed |
| US-9820972-B2 | Antiviral compounds highly effective as HCV-NS5A inhibitor | AB Pharma Ltd. (CN) | 2017-11-21 | — | — | US | disclosed |
| EP-3153515-A1 | COMPOUNDS FOR INHIBITING HEPATITIS C VIRUS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | AB Pharma Ltd (CN) | 2017-04-12 | — | — | EP | disclosed |
| US-20160229866-A1 | HEPATITIS C VIRUS INHIBITORS | IDENIX PHARMACEUTICALS INC. (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160136134-A1 | ANTIVIRAL COMPOUNDS HIGHLY EFFECTIVE AS HCV-NS5A INHIBITOR | AB Pharma Ltd. (CN) | 2016-05-19 | — | — | US | disclosed |
| US-9334291-B2 | Antiviral compounds highly effective as HCV-NS5A inhibitor | AB Pharma Ltd. (CN) | 2016-05-10 | — | — | US | disclosed |
| US-9187496-B2 | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors | IDENIX PHARMACEUTICALS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140364429-A1 | ANTIVIRAL COMPOUNDS HIGHLY EFFECTIVE AS HCV-NS5A INHIBITOR | AB Pharma Ltd. (CN) | 2014-12-11 | — | — | US | disclosed |
| US-8362068-B2 | 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120252721-A1 | METHODS FOR TREATING DRUG-RESISTANT HEPATITIS C VIRUS INFECTION WITH A 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITOR | IDENIX PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20110150827-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2011-06-23 | — | — | US | disclosed |
| EP-1715840-B1 | KERATIN DYEING COMPOSITIONS CONTAINING BICYCLIC FUSED 5-5 HETEROAROMATIC DYES | PROCTER & GAMBLE (US) | 2008-12-03 | — | — | EP | disclosed |
| US-7303590-B2 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| EP-1715840-A1 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING THEM, AND USE THEREOF | The Procter and Gamble Company (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20050193502-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | PROCTER, GAMBLE COMPANY, THE | 2005-09-08 | — | — | US | disclosed |
| WO-2005077324-A1 | KERATIN DYEING COMPOUNDS, KERATIN DYEING COMPOSITIONS CONTAINING THEM, AND USE THEREOF | THE PROCTER & GAMBLE COMPANY (US) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150827-A1 | 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS | HAVCR2, CYP3A5, CYP2E1 | SMYD3 4774/4885NOS1 3825/4885KEAP1 214/4885 |
| US-20160136134-A1 | ANTIVIRAL COMPOUNDS HIGHLY EFFECTIVE AS HCV-NS5A INHIBITOR | MAVS, HAVCR2, EIF2AK2 | SMYD3 4567/4885NOS1 3105/4885KEAP1 319/4885 |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | NSD3, PML, NSD1 | SMYD3 272/4885NOS1 3594/4885KEAP1 1700/4885 |
| US-20140364429-A1 | ANTIVIRAL COMPOUNDS HIGHLY EFFECTIVE AS HCV-NS5A INHIBITOR | MAVS, HAVCR2, EIF2AK2 | SMYD3 4567/4885NOS1 3105/4885KEAP1 319/4885 |
| US-20050193502-A1 | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof | KRT18, KLK5, CKMT1A; CKMT1B | SMYD3 1240/4885NOS1 1863/4885KEAP1 172/4885 |
| US-20120252721-A1 | METHODS FOR TREATING DRUG-RESISTANT HEPATITIS C VIRUS INFECTION WITH A 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITOR | HAVCR2, CYP3A5, CYP7A1 | SMYD3 4366/4885NOS1 3779/4885KEAP1 460/4885 |
| US-20160229866-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, LIPC, LDHB | SMYD3 2303/4885NOS1 4609/4885KEAP1 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.